We are excited to announce that patients at Retina Health Center are among the first in the nation to have access to SYFOVRE™ (PEGCETACOPLAN INJECTION). SYFOVRE™ is a new FDA-approved drug from Apellis Pharmaceuticals that can slow the progression of retina damage caused by Dry Age-related Macular Degeneration.
This is a significant innovation for people living with Dry Age-related Macular Degeneration with geographic atrophy, as it is the first and only drug on the market proven in clinical trials to curtail geographic atrophy growth, which is the main cause of severe vision loss in patients with Dry AMD.
We are proud to offer our patients the most advanced and effective treatment options for their retina health needs. The newly approved SYFOVRE™ drug is another tool in our toolbox that we can use to treat Dry AMD for patients in Southwest Florida. Please give us a call if you would like to secure an appointment sooner to discuss whether or not this treatment may be right for you.